CU6 Share Price Performance
AU$4.82
-2.03 (-29.64%)
Price AU$4.82
Share PriceAU$4.82
Clarity Pharmaceuticals Ltd Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 42 Fair Values set on narratives written by author
CU6 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Clarity Pharmaceuticals Ltd Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.17
- 100.00%
- -679.45%
- 0%
About CU6
- Founded
- 2010
- Employees
- 69
- CEO
- WebsiteView website
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
